Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain.
Mov Disord. 2010 Dec 15;25(16):2735-9. doi: 10.1002/mds.23219.
Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1%). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.
帕金森病 (PD) 可以通过标准治疗进行症状控制;然而,几年后,这种反应通常会下降,大多数患者会出现运动并发症。我们进行了一项前瞻性基于实践的研究,以评估 64 例新诊断的 PD 患者在 5 年内和 38 例 PD 患者在 10 年内的运动并发症的出现和演变。我们研究了未接受治疗的患者,从基线条件下的初始评估开始,并在随后的每 6 个月进行治疗(左旋多巴与其他药物)评估。随访评估采用统一帕金森病评定量表 (UPDRS) 进行。在每次评估中,监测患者是否出现运动障碍、运动波动、冻结、姿势反射丧失和认知障碍。我们观察到,在第一年,UPDRS 评分显著改善,然后逐渐下降,在第三年后更为明显。运动并发症在第三年后增加,在调查结束时(第十年);出现了药物诱导的运动障碍和运动波动(分别为 71.1%和 94.7%)。在第一个十年后,许多并发症是由于疾病的非左旋多巴反应特征引起的(认知障碍的发生率为 52.6%,步态冻结的发生率为 71.1%)。初始药物可能会影响中期并发症,但不会影响长期问题。大多数 PD 的长期致残问题与非左旋多巴反应特征有关。